FGF8 promotes cell proliferation and resistance to EGFR inhibitors via upregulation of EGFR in human hepatocellular carcinoma cells
Y Pei, X Sun, X Guo, H Yin, L Wang… - Oncology …, 2017 - spandidos-publications.com
Abstract Fibroblast growth factor 8 (FGF8), a member of the fibroblast growth factor (FGF)
family, is upregulated in several human cancers, including HCC (HCC). Previous studies …
family, is upregulated in several human cancers, including HCC (HCC). Previous studies …
Insights into growth factors in liver carcinogenesis and regeneration: An ongoing debate on minimizing cancer recurrence after liver resection
AI Álvarez-Mercado, A Caballeria-Casals… - Biomedicines, 2021 - mdpi.com
Hepatocellular carcinoma has become a leading cause of cancer-associated mortality
throughout the world, and is of great concern. Currently used chemotherapeutic drugs in the …
throughout the world, and is of great concern. Currently used chemotherapeutic drugs in the …
Erlotinib and sorafenib in an orthotopic rat model of hepatocellular carcinoma
W Sieghart, M Pinter, B Dauser, N Rohr-Udilova… - Journal of …, 2012 - Elsevier
BACKGROUND & AIMS: The combination of erlotinib with sorafenib is currently being
investigated in a phase III RCT. We studied the effect of erlotinib and sorafenib on HCC in a …
investigated in a phase III RCT. We studied the effect of erlotinib and sorafenib on HCC in a …
Molecular biology of epidermal growth factor receptor inhibition for cancer therapy
S Oliveira… - Expert Opinion on …, 2006 - Taylor & Francis
Understanding the role of the epidermal growth factor receptor (EGFR) in cellular signalling
processes underlying malignancy has enabled the development of rationally designed …
processes underlying malignancy has enabled the development of rationally designed …
Conserved and tissue-specific genic and physiologic responses to caloric restriction and altered IGFI signaling in mitotic and postmitotic tissues
SR Spindler, JM Dhahbi - Annu. Rev. Nutr., 2007 - annualreviews.org
Caloric restriction (CR), the consumption of fewer calories without malnutrition, and reduced
insulin and/or IGFI receptor signaling delay many age-related physiological changes and …
insulin and/or IGFI receptor signaling delay many age-related physiological changes and …
Enhanced anti‐angiogenic effect of E 7820 in combination with erlotinib in epidermal growth factor receptor–tyrosine kinase inhibitor‐resistant non‐small‐cell lung …
K Ito, T Semba, T Uenaka, T Wakabayashi… - Cancer …, 2014 - Wiley Online Library
Most non‐small‐cell lung cancers (NSCLC s) harboring activating mutations in the
epidermal growth factor receptor (EGFR) are initially responsive to EGFR tyrosine kinase …
epidermal growth factor receptor (EGFR) are initially responsive to EGFR tyrosine kinase …
Genetic diversity of hepatocellular carcinomas and its potential impact on targeted therapies
J Zucman-Rossi, P Laurent-Puig - Pharmacogenomics, 2007 - Taylor & Francis
Hepatocellular carcinoma (HCC) is one of the most frequent solid tumors worldwide and
represents the third cause of mortality among deaths from cancer. It has been extensively …
represents the third cause of mortality among deaths from cancer. It has been extensively …
Development of 1, 5-diarylpyrazoles as EGFR/JNK-2 dual inhibitors: design, synthesis, moleecular docking, and bioactivity evaluation
OM Soltan, SA Abdel-Aziz, MS Shaykoon… - Bioorganic & Medicinal …, 2024 - Elsevier
The eradication of multifactorial diseases, such as cancer, requires the design of drug
candidates that attack multiple targets that contribute to the progression and proliferation of …
candidates that attack multiple targets that contribute to the progression and proliferation of …
The major vault protein mediates resistance to epidermal growth factor receptor inhibition in human hepatoma cells
A Losert, D Lötsch, A Lackner, H Koppensteiner… - Cancer letters, 2012 - Elsevier
To better understand the response of HCC to EGFR inhibition, we analyzed factors
connected to the resistance of HCC cells against gefitinib. Sensitive HCC3 cells co …
connected to the resistance of HCC cells against gefitinib. Sensitive HCC3 cells co …
Design, synthesis and biological study of hybrid drug candidates of nitric oxide releasing cucurbitacin-inspired estrone analogs for treatment of hepatocellular …
MA Abou-Salim, MA Shaaban, MK Abd El Hameid… - Bioorganic …, 2019 - Elsevier
Abstract Development of hybrid drug candidates is well known strategy for designing
antitumor agents. Herein, a novel class of nitric oxide donating cucurbitacin inspired estrone …
antitumor agents. Herein, a novel class of nitric oxide donating cucurbitacin inspired estrone …